Abstract
SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH) developed to facilitate monitoring and ablation of differentiated thyroid carcinoma (DTC) without the debilitating effects of clinical hypothyroidism. This Phase I, dose-ascending study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SNA001 in 24 DTC patients across three dose levels (0.45 mg, 0.9 mg, and 1.35 mg). The study utilized a two-period design comparing SNA001-stimulated testing with traditional thyroid hormone withdrawal (THW). Results demonstrated that SNA001 is safe, exhibits dose-dependent metabolism, and achieves 100% qualitative diagnostic concordance with THW in whole-body scans (WBS). SNA001 effectively stimulates iodine-131 uptake and thyroglobulin (Tg) release while maintaining patient quality of life.
Introduction
Patients with differentiated thyroid carcinoma (DTC) require lifelong monitoring to detect recurrence or metastasis. Effective diagnostic tools, such as radioactive iodine-131 whole-body scans (WBS) and serum thyroglobulin (Tg) measurements, require elevated thyroid-stimulating hormone (TSH) levels (typically >30 mU/L) to maximize sensitivity. Historically, this elevation was achieved through Thyroid Hormone Withdrawal (THW), which requires patients to stop replacement therapy for several weeks, leading to severe clinical hypothyroidism.
While recombinant human TSH (rhTSH) alternatives like Thyrogen™ exist globally, they have not been available in mainland China. SNA001 was developed as a novel rhTSH analog to provide the necessary TSH spike without the physiological burden of withdrawal. This paper evaluates the clinical performance of SNA001 in a Phase I trial.
Methods
The researchers conducted a single-center, open-label, dose-ascending Phase I clinical trial involving 24 DTC patients who had previously undergone thyroidectomy. The study followed a unique two-period design to compare the novel drug against the established gold standard.
In the SNA001 Period, patients received two intramuscular injections of SNA001 (0.45 mg, 0.9 mg, or 1.35 mg) 24 hours apart while continuing their thyroid hormone therapy. Diagnostic testing (WBS and Tg) was performed following the injections. After a washout period of at least two weeks, patients entered the THW Period, where they ceased hormone therapy for 3–6 weeks until TSH levels naturally rose above 30 mU/L, at which point the diagnostic tests were repeated for comparison.
Results
Pharmacokinetics and Pharmacodynamics
SNA001 demonstrated linear, dose-proportional pharmacokinetics. Mean peak serum concentrations (Cmax) for the 0.45, 0.9, and 1.35 mg groups were 18.5, 26.7, and 37.0 ng/ml, respectively.
Crucially, the 1.35 mg dose was most effective at maintaining TSH levels above the 30 mU/L clinical threshold for a sufficient diagnostic window (3–4 days). No patients developed anti-TSH antibodies, indicating low immunogenicity.
Diagnostic Concordance and Quality of Life
The primary clinical success was the 100% qualitative concordance in WBS results between the two periods. Every lesion or area of residual tissue identified during the THW period was also successfully identified during the SNA001 period. While absolute Tg levels were generally higher in the THW period (in 78% of subjects), SNA001 stimulated Tg levels above the 1 ng/ml diagnostic cutoff in 89% of patients, proving sufficient for clinical monitoring.
Quality of life assessments showed that SNA001 successfully avoided the symptoms associated with THW, such as fatigue, weight gain, and constipation. The safety profile was excellent, with only mild, transient gastrointestinal adverse events reported.
Discussion and Conclusion
This Phase I trial confirms that SNA001 is a safe and effective alternative to thyroid hormone withdrawal for DTC patients. By providing a predictable TSH spike, it allows for accurate diagnostic imaging and biochemical testing without the morbidity of hypothyroidism.
While the study was limited by its small sample size and single-center nature, the results are highly promising. A Phase III confirmatory trial is currently underway to further validate these findings. If approved, SNA001 will offer a significant advancement in the standard of care for thyroid cancer patients in China, prioritizing both diagnostic accuracy and patient well-being.
Summary updated